What to Expect at the LNP Analytical Meeting
in 2025?
Curated in collaboration with leading analytical experts and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit is a forum focused on advancing LNP analytics and characterization to deliver high-quality, efficacious LNPs to patients in need.
Join more than 90 experts in analytics, assays, characterization, and CMC for three comprehensive days of in-depth discussions and data-driven presentations. Together, we will define robust analytical strategies to support regulatory submissions and accelerate the development of genomic medicines.
I see great value in attending the LNP Characterization & Analytical Development Summit. This event offers an excellent opportunity to collaborate with experts, discuss innovative techniques, and tackle challenges in LNP stability, efficacy, and regulatory submissions. By participating, I aim to share knowledge, gain insights, and contribute to driving progress in LNP characterization to support the development of genetic medicine
Jikang Wu, Senior Principal Scientist,
Regeneron
Unmissable Agenda Highlights:
the limitations of gold standard QC release assays by leveraging orthogonal techniques for more accurate LNP analysis, with insights from Pfizer and GSK
robust analytical strategies for characterizing and separating multivalent LNPs to accelerate approval of LNP-mediated gene editing medicines, with insights from Novo Nordisk, Sanofi and Prime Medicine
insights into innovative, advanced assays for targeted LNPs to enable precise understanding of surface functionalization and LNP composition, with insights from Mote Therapeutics and Tessera Therapeutics
advanced imaging methods, such as SAXS and cryo-EM, to evaluate LNP morphology and potency for improving LNP delivery performance, with insights from Pfizer and Suzhou Abogen Biosciences
LNP analytical insights with process performance to advance more LNP drug products from R&D to CMC and towards regulatory approval, with insights from Takeda, Beam Therapeutics and GSK
Key Sessions Not to Miss:
“Optimizing Dual-Cargo Delivery: Advanced Characterization Techniques for Gene Editing with Lipid Nanoparticles” - Elias Halabi, Senior Scientist II, Novo Nordisk
“Analyzing In Vivo Delivery of RNA by Targeted Lipid Nanoparticles (tLNP) to Hematopoietic Stem Cells & T-cells in Humanized Mice & Non-Human Primates” - Mohit Gupta, Principal Scientist, Tessera Therapeutics
“Advanced Analytical Tools for Understanding Gaps Between Physico-Chemical Property & In Vivo Potency” - Qook Lee, Research Advisor, Eli Lilly & Co
“Aligning Analytical Insights with Process Performance for Improving Process Optimization for Higher Quality & More Stable LNPs” - Kanika Suri, Scientist, Takeda Pharmaceuticals
“Enhancing LNP Morphology & Potency by Leveraging Cryo-EM to Improve LNP Delivery Performance” - Pushkar Saralkar, Senior Scientist, Pfizer